Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

NCT02136511 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: Idelalisib
DRUG: Rituximab

Sponsor

Gilead Sciences